disease development, owing to abnormal host responses directed against the commensal microbiota. 1, 2 Key clinical signs include vomiting, diarrhea and weight loss, and histopathologic lesions of inflammation can involve the stomach, small intestine, and/or colon. 3, 4 The diagnosis is based on gastrointestinal biopsies and exclusion of other causes of chronic signs of gastrointestinal disease. 3 Current treatment strategies aim at reducing and eliminating intestinal inflammation. Specific guidelines for treatment of IBD include some combination of dietary and drug treatment with the optimal protocol yet to be defined.
The current assessment of IBD is based on clinical signs and disease activity scores alone might have limitations. Despite clinical remission, many dogs have ongoing histopathologic inflammation with low clinical activity scores, 5 which could underestimate disease activity.
Therefore, the search for biologic markers that can assess temporal changes in clinical activity and predict the clinical course of IBD in dogs has become an important focus of IBD research. Knowledge of the degree of inflammation at different stages of the disease can help clinicians make important management decisions. In addition, considering that endoscopy is expensive, influenced by operator experience, and a relatively invasive procedure, the addition of laboratory markers to clinical indices would be an attractive option for defining disease severity.
Importantly, in human medicine, biomarkers are often used to identify patients with low-grade inflammation, to monitor for remission, and to identify flares before the development of clinical signs, which would allow for pre-emptive escalation of treatment. 6 In humans, C-reactive protein (CRP) is consistently a useful IBD activity marker as it correlates with clinical disease activity and histologic inflammation and is useful in predicting relapse of disease. [7] [8] [9] Additionally, it might identify patients with low-grade histopathologic inflammation and it is useful for assessing the efficacy of drug treatment. 7, 10 Fecal calprotectin is among the most used and reliable fecal markers for IBD in humans. 11 Concentrations of fecal calprotectin in humans with IBD have been correlated to disease activity, endoscopic findings, and the degree of histologic inflammation. [12] [13] [14] [15] In human patients with ulcerative colitis, 50%-80% have antibodies to perinuclear antineutrophilic cytoplasmic antibodies (pANCA) 16 while most patients (70%-90%) with Crohn's disease are negative for pANCA. [17] [18] [19] In our study, we hypothesized that different serum and fecal biomarkers (serum CRP, pANCA, and calprotectin as well as fecal calprotectin) are increased in dogs with idiopathic IBD before medical treatment compared with healthy control dogs, and that these markers change in response to standard medical treatment. We also hypothesized that serologic and fecal biomarkers correlate with disease severity indices, including the Canine IBD activity index (CIBDAI) score and the severity of histopathopathologic inflammation. The gastric and duodenal histopathology scores were then added to form the overall (total) histopathology score. Additional tests such as fecal examination for nematodes and protozoan parasites (n 5 16), specific pancreatic lipase concentration (n 5 11 dogs), serum cobalamin concentration (n 5 9 dogs), serum folate concentration (n 5 9 dogs), and serum trypsin-like immunoreactivity (n 5 9 dogs) were not part of the inclusion criteria and were performed at the attending clinician's discre- For the healthy control group, blood and a single fecal sample were obtained during physical examination at study enrollment for determination of healthy control measurements of serum CRP, cCP, and pANCA, and fecal cCP. 
| M A TE RI A L S A ND M E TH ODS

| Study population
| Serum and fecal cCP assay
Serum and fecal calprotectin concentrations were determined via a species-specific enzyme-linked immunosorbent assay developed and analytically validated at the Gastrointestinal Laboratory at Texas A&M University. 23, 24 Spot fecal samples (1.0 6 0.3 g) were collected from all dogs at the time of 1st visit and at reevaluation. Samples were stored frozen (-208C or 2808C) until sample analysis within 2-20 months.
Fecal samples were then thawed and extracted, and biomarker concentrations were measured in 2 batches of all specimens. 25 
| Statistical analyses
Given the sample size and that not all of the interval-measured variables were normally distributed, both interval-measured variables and the ordinal (score) variables are reported as medians (ranges) After histopathologic diagnosis, all dogs were treated with an immunosuppressive agent (prednisone alone, n 5 13; enteric-coated budesonide, n 5 1; and prednisone in combination with cyclosporine, n 5 2) at the attending clinician's discretion. Antibiotics were also administered to some dogs at the clinician's discretion (metronidazole alone, n 5 4; and metronidazole, amoxicillin, and clarithromycin in combination for gastric spiral bacteria (suspect Helicobacter spp. infection).
treatment, n 5 1).
| Clinical activity scores and response to treatment
Based on the CIBDAI scores at diagnosis, there were 4 dogs with mild disease severity (score between 4 and 5), 6 dogs with moderate disease activity (score 6-8), and 6 dogs with severe clinical disease (score >9).
There was a statistically significant reduction in clinical severity scores (P < .001; Figure 1 ) from before to after treatment scores. while one dog failed to respond (CIBDAI score increased from 6 to 8 from before to after treatment).
| Serum CRP concentration
The median serum CRP concentration in healthy control dogs was 
| Serum cCP concentration
The median serum cCP concentration in healthy control dogs was 
| Correlations between serum and fecal biomarkers and the severity of histopathologic lesions
Overall histopathologic severity scores (median: 3.5, range: 2-5) were not associated with serum CRP or cCP concentrations (P 5 .73 and .37, respectively), fecal cCP concentrations (P 5 .07), nor serum pANCA positivity (P 5 .87) before treatment. In addition, no correlations were detected between these biomarkers and the severity of gastric lesions (P 5 .80, .52, .61, and .31, respectively) or duodenal scores (P 5 .23, .39,
.09, and .23, respectively).
| Correlations between the severity of clinical disease and histologic lesions
A weak positive association was detected between the CIBDAI scores before treatment and the overall histopathologic lesion score (rho 5 0.53, P 5 .03), of which there was a moderate correlation with the duodenal lesion score (rho 5 0.64, P 5 .01) but no association with the gastric lesion score (P 5 .36). There was no correlation between CIBDAI scores after treatment and the overall histopathologic lesion scores (P 5 .49).
| D I SCUSSION
Our study describes measurements of serum and fecal biomarker concentrations in healthy dogs and dogs with idiopathic IBD before and after short-term (induction treatment for 3 weeks) treatment. In our study, fecal cCP was significantly increased at diagnosis in dogs with IBD when compared with healthy dogs, and decreased significantly in response to treatment. This is similar to one previous veterinary study comparing healthy dogs and dogs with chronic diarrhea. 26 Our findings are also similar to those described in human patients [12] [13] [14] 27 suggesting that fecal cCP is a useful candidate biomarker for noninvasive evaluation of intestinal inflammation. In humans, fecal calprotectin has also been used to monitor clinical disease severity and to differentiate active and quiescent Crohn's disease in adults and children. 28 A recent meta-analysis evaluating the role of fecal calprotectin during the initial investigation of children with suspected IBD concluded that fecal calprotectin was a useful screening tool in patients requiring further endoscopic assessment with 95% sensitivity and specificity. 29 Our results also showed a positive correlation between fecal cCP concentrations and CIBDAI scores before treatment. This is a relevant finding since clinical score has been previously correlated to negative outcome. 30 Additionally, there was a trend for a positive correlation between fecal cCP and histopathologic scores, which is also similar to a previous study in dogs. 26 Unlike fecal cCP, serum cCP concentrations did not differ significantly between healthy dogs and dogs with IBD. Some dogs with IBD had an increased serum cCP that was not different from controls, and serum cCP did not decrease in response to treatment. Calprotectin is significantly higher in dogs with IBD (at diagnosis) when compared with healthy control dogs. 31 However, the sensitivity and specificity to differentiate healthy and dogs with IBD with an established cutoff, was only 82.4% and 68.4%, respectively. 31 No significant difference in serum calprotectin concentrations was found in Shar-Pei dogs when compared with those dogs without hypocobalaminemia. 32 Serum biomarkers and survival times in dogs with protein-losing enteropathy and foodresponsive diarrhea reveal increased serum calprotectin in both groups, but not a significant difference in the magnitude of serum calprotectin between both groups. 33 Our results support previously established data supporting that serum cCP might not be an ideal marker for IBD.
C-reactive protein has been considered a sensitive biomarker of inflammation. Similar to previous results, CRP was significantly increased at diagnosis of idiopathic IBD when compared with healthy dogs as well as dogs with IBD after treatment. 21, 34 Our results were also in accordance with previously published results showing a lack of correlation between CRP concentration and CIBDAI in dogs with idiopathic IBD 35 or histopathologic lesion score in dogs with chronic enteropathy. 30 Even though previous results showed a lack of positive correlation between CIBDAI score and serum CRP concentration, there was a separate study that showed an association between these. 34 We suspect that this difference in the results of the earlier study included a larger number of diseased dogs with moderate-to-severe IBD clinical scores. Therefore, it is possible that we would have seen a significant association between CIBDAI scores and serum CRP concentrations with a larger sample size.
In our study, pANCA was not found to be a useful marker of intestinal inflammation. Previously, it was found that assays for pANCA in dogs with IBD had a sensitivity of 51%; the specificity of pANCA
Fecal calprotectin concentrations before and after IBD treatment. *P < .001
ranged from 82% to 95%. 36 In addition, serum pANCA was evaluated for diagnostic purposes and to assess response to treatment in dogs with IBD or food responsive disease (FRD). 37 The same study revealed that 62% of the dogs with FRD were pANCA positive at diagnosis and only 23% of dogs with IBD were positive before treatment. It was concluded that the pANCA status might be helpful in differentiating dogs with FRD from dogs with IBD before treatment. 37 Assays for measurement of pANCA have also been evaluated in dogs with IBD, and have shown variable sensitivities from 25% to 43%, with specificities ranging from 85% to 94%. 22 Recently, pANCA was evaluated in dogs with IBD and intestinal lymphoma 38 and indicated that circulating pANCA are present in some dogs with IBD and intestinal lymphoma. However, the results indicated that pANCA detection does not seem to be useful for distinguishing dogs with IBD from dogs with intestinal lymphoma. Our study had encouraging results, especially in regards to fecal cCP. Fecal markers correlate better with mucosal healing and disease activity than serologic markers in humans. 39 Fecal calprotectin is the mostly investigated biomarker in humans with IBD 40 and it is one of the more widely used noninvasive tests. 41 Historically, human IBD patients were monitored for disease relapse based on subjective variables such as clinical signs, as current practice in veterinary medicine.
However, this traditional approach has problems such as delayed initiation of effective treatment and poor correlation between clinical signs and disease activity as defined by endoscopy. 42 Rather, regular assessment of disease activity during remission via objective endoscopic and biological markers allows for closer monitoring and help to identify patients at higher risk of recurrence and thus requiring treatment adjustments. Moreover, it is known that failure to control intestinal inflammatory in human patients with IBD is associated not only with impaired quality of life of patients but also worse long-term outcomes, including increased potential for colonic carcinogenesis. 43, 44 Considering that fecal cCP is increased in untreated dogs with IBD and decreases significantly after induction treatment, it has the potential to be serially used, as in human patients, as a non-invasive marker to monitor disease severity, differentiate active and quiescent disease and possibly predict disease flare-ups. Furthermore, similarly to veterinary patients, endoscopic assessment is often difficult in children because of the need for general anesthesia and bowel preparation requirements.
Several studies evaluating the role of fecal calprotectin during the initial investigation of children with suspected IBD showed that screening calprotectin feces test has accurately helped clinicians decide whether or not to refer the patient for endoscopy. 29, 45, 46 This could be useful for veterinarians clinicians to decide the need for more invasive and costly tests such as endoscopy.
Fecal calprotectin in humans is used to monitor and predict disease response to treatment, 47 to adjust treatment, and to identify patients at increased risk of relapse. 48 In dogs with IBD, duration and reinstitution of medical treatment is largely subjective and based solely on clinical signs. It would be advantageous to be able to better tailor treatment and the need for repeat endoscopy based on more objective and less invasive markers such as fecal calprotectin. Factors such as breed and age could affect concentration of acute phase protein concentrations and it is desirable to control for these possible confounding factors when investigating these variables. While there was a difference in age between the healthy and dogs with IBD, there was an obvious improvement on these measurements before and after treatment. In human patients with IBD, the variation in CRP for example is more important to identify active versus quiescent disease within the same individual instead of comparing it to others. 49 A study for validation of fecal and serum calprotectin showed no significant difference in fecal calprotectin among pet dogs of various age groups (0.8-11.1 years of age), which might suggest that age related changes do not occur. 50 Unfortunately, age-matching the healthy dogs was not possible in our study because of limited time and resources of the study. 51 Further research is needed to adjudicate this matter in pet dogs. Additionally, collection of feces for calprotectin measurement is recommended to be from natural defecation. 50 Therefore, it could be argued that feces from dogs with IBD collected in the hospital while 
